LakeShore Biopharma Co., Ltd
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LSBCF research report →
Companywww.ysbiopharm.com
LakeShore Biopharma Co. , Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
- CEO
- Wang Xu
- IPO
- 2021
- Employees
- 758
- HQ
- Beijing, CN
Price Chart
Valuation
- Market Cap
- $1.52M
- P/E
- -0.27
- P/S
- 0.02
- P/B
- 0.05
- EV/EBITDA
- -8.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 82.47%
- Op Margin
- -14.03%
- Net Margin
- -16.26%
- ROE
- -18.43%
- ROIC
- -9.15%
Growth & Income
- Revenue
- $614.96M · 7.24%
- Net Income
- $-99,982,451 · 76.93%
- EPS
- $-0.94 · 76.79%
- Op Income
- $-86,291,884
- FCF YoY
- 59.10%
Performance & Tape
- 52W High
- $1.48
- 52W Low
- $0.03
- 50D MA
- $0.04
- 200D MA
- $0.54
- Beta
- 0.11
- Avg Volume
- 4.04K
Get TickerSpark's AI analysis on LSBCF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LSBCF Coverage
We haven't published any research on LSBCF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LSBCF Report →